Malignant Solid Tumors
27
10
10
10
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 27 trials
100.0%
+13.5% vs benchmark
7%
2 trials in Phase 3/4
20%
2 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (27)
Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors
A Study of TAK-505 in Adults With Solid Tumors
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors
Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
A Phase I/II Clinical Study of SHR-1681 for Injection in Patients With Advanced Solid Tumors
A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
Nanocrystalline Megestrol for Managing Chemotherapy-Induced Nausea and Vomiting
The Effect of Serum Ferritin in irAE
Evaluate the Safety and Tolerability of JCXH-212 Monotherapy and Combined With Toripalimab in the Treatment of Malignant Solid Tumors
Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research
Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
First in Human Study of 68Ga/64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors
An Observational Study, Called ROCURS, to Learn About COVID-19 Related Outcomes in People With Cancer Who Are Treated With Tyrosine Kinase Inhibitors (TKIs) Including Regorafenib or Sorafenib
A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients
A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors
Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas